[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"noninvasive-brain-stimulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:noninvasive-brain-stimulation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100628434","early-phase-1-memory-enhancement-in-aging-with-optimal-dosing-100628434",false,"NCT07461584","Memory Enhancement in Aging With Optimal Dosing","Personalized Memory Enhancement in Aging: Pattern-Optimized tACS With Closed-Loop Precision Modulation","Inclusion Criteria:\n\n* 65 years of age or older\n* normal or corrected-to-normal vision\n* color vision\n\nExclusion Criteria:\n\n* pregnant\n* metal implants in head\n* implanted electronic devices\n* history of neurological problems or head injury\n* skin sensitivity\n* claustrophobia\n* dementia (normal Montreal Cognitive Assessment \\> 25)\n* depression (normal Geriatric Depression Scale \\\u003C 10)\n* history of psychosis\n* cognitive deficits (MoCA\\>25)\n* any psychoactive medication",true,"ALL","65 Years",{"count":20,"type":21},240,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","This project optimizes high-resolution tACS to improve memory in healthy older adults, advancing drug-free approaches for ADRD. We test stimulation schedules and develop an adaptive, brain-guided tACS system to strengthen memory-supporting networks.",[27,28,29],"Aging","Noninvasive Brain Stimulation","Memory","NOT_YET_RECRUITING","2026-04-01",{"date":33,"type":34},"2026-04-07","ACTUAL",{"date":36,"type":21},"2026-05-01",{"date":38,"type":21},"2031-01-31",{"name":40,"class":41},"Boston University Charles River Campus","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":4},"100608958","early-phase-1-restructuring-the-alpha-gamma-code-in-aging-vision-100608958","NCT07208318","Restructuring the Alpha-Gamma Code in Aging Vision","Rescuing Visual Perception in Aging Adults by Restructuring the Alpha-Gamma Neural Code","Inclusion Criteria:\n\n* 18+ years of age or older\n* normal or corrected-to-normal visual acuity, color vision, and stereo vision\n\nExclusion Criteria:\n\n* not pregnant,\n* no metal implants in head,\n* no implanted electronic devices,\n* no history of neurological problems or head injury,\n* no skin sensitivity,\n* no claustrophobia,\n* no dementia (normal Mini Mental State Examination between 24-30; Montreal Cognitive Assessment \\> 25)\n* no depression (normal Beck Depression Inventory II \\\u003C13; Geriatric Depression Scale \\\u003C 10)\n* no ophthalmological diseases (e.g., strabismus, glaucoma, cataract, macular degeneration)\n* no history of psychosis\n* no cognitive deficits (MMSE score\\>24; MoCA\\>25)\n* cannot be taking any psychoactive medication.","18 Years",{"count":20,"type":21},[24],"Tests whether age-related visual deficits arise from disrupted alpha-gamma coupling in visual cortex (V1) and MT. Uses fMRI, source-resolved HD-EEG, and personalized complex-waveform HD-tACS to (1) quantify aging effects on phase-amplitude coupling, (2) drive PAC into a preferred \"gamma-at-alpha-troughs\" state, and (3) bidirectionally change perception by aligning gamma to alpha troughs vs peaks. Two five-day, double-blind, sham-controlled studies (n=120 each) target contrast sensitivity (V1) and 3D shape-from-motion (MT), aiming for mechanistic insight and remediation in older adults with implications for ADRD.",[27,54,28],"Visual Perception","2025-09-27",{"date":57,"type":34},"2025-10-06",{"date":59,"type":21},"2026-01-10",{"date":61,"type":21},"2030-08-31",{"name":40,"class":41}]